Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.7552W HIGH $12.18
Volume
1.21 K
Value Traded
260.74 K
Short % Float
0.21%
+1.22%Week
-13.02%1 Month
+15.05%3 Month
-5.99%6 Month
-79.19%5 Year
-78.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
544.64 M
EPS (TTM)
-1.87
P/E Ratio
-
Ent. Value
664.58 M
Total Shares
94.82 M
Float Shares
91.77 M
Insiders
3.22%
Institutions
0.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VALN Catalyst Timeline
Dated clinical, regulatory and corporate events for Valneva SE
Catalyst Timeline
Dated clinical, regulatory & corporate events for Valneva SE
513Total events
11Upcoming
198Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Drug WithdrawalIXCHIQDiscontinuedFDA Decision
MHRA revokes UK marketing authorization for IXCHIQ following CHM benefit-risk assessment
chikungunyasource ↗
▲Quarterly UpdateIXIAROCorporate
New IXIARO contract with U.S. DoD expected in Q3 2026
Japanese encephalitissource ↗
●Product LaunchIXIAROPost-Market
New IXIARO contract with U.S. DoD expected in Q3 2026
Japanese encephalitissource ↗
◆Poster PresentationPresentation
10th Northern European Conference on Travel Medicine (NECTM10) Gold Sponsor and Exhibitor
◆Topline ReadoutS4V2Clinical Data
First Phase 2 data for tetravalent Shigella vaccine candidate S4V2
Shigellosissource ↗
▲Topline ReadoutLB6VClinical Data
Pfizer reported topline Phase 3 results for LB6V demonstrating strong efficacy with no safety concerns
Lyme diseasesource ↗
▲Other Regulator MilestoneIXCHIQDiscontinuedEx-US Regulatory
ANVISA authorized Instituto Butantan to locally manufacture a version of IXCHIQ
Chikungunyasource ↗
▼Restructuring LayoffsCorporate
Initiated further restructuring plan including workforce reduction
◆Oral PresentationPresentation
Van Lanschot Kempen Life Sciences Conference investor meetings
◆Oral PresentationIXCHIQDiscontinuedPresentation
Panel discussion on chikungunya and mosquito-borne vaccines at World Vaccine Congress
chikungunyasource ↗
▼Equity OfferingCorporate
Reserved offering completed in Q2 2026 with €37 million gross proceeds
▲Enrollment MilestoneIXCHIQDiscontinuedTrial
Pilot vaccination campaign launched in Brazil; over 12,000 vaccinated
chikungunyasource ↗
▲Enrollment UpdateIXCHIQDiscontinuedTrial
Pilot vaccination campaign in Brazil with IXCHIQ: over 12,000 people vaccinated
chikungunyasource ↗
●Quarterly UpdateCorporate
Publication of audited consolidated financial results for fiscal year 2025
◆Topline ReadoutLB6VClinical Data
Topline results from Phase 3 VALOR trial announced in March 2026
Lyme diseasesource ↗
◆Safety Label ChangeIXCHIQDiscontinuedPost-Market
UK MHRA updates IXCHIQ prescribing information with restrictions for individuals over 60 and those with specified health conditions
chikungunyasource ↗
▲Trial InitiationIXCHIQDiscontinuedTrial
Launch of pilot vaccination campaign in Brazil with IXCHIQ
chikungunyasource ↗
▲Trial InitiationIXCHIQDiscontinuedTrial
Pilot vaccination campaign launched in Brazil with IXCHIQ
Chikungunyasource ↗
▲Partnership / LicenseIXCHIQDiscontinuedCorporate
Start of pilot vaccination strategy in Brazil with Instituto Butantan
Chikungunyasource ↗
▼BLA SubmissionIXCHIQDiscontinuedRegulatory Filing
Voluntary withdrawal of BLA for IXCHIQ in the US
chikungunyasource ↗
▼IND WithdrawalIXCHIQDiscontinuedIND
Voluntary withdrawal of IND for IXCHIQ in the US
chikungunyasource ↗
▼Clinical Hold PlacedIXCHIQDiscontinuedIND
FDA placed IND on clinical hold pending investigation of SAE
chikungunyasource ↗
▼Serious Ae Or DeathIXCHIQDiscontinuedSafety
Serious Adverse Event reported outside US in younger adult who received three concomitant vaccines including IXCHIQ
chikungunyasource ↗
▼IND SubmissionIXCHIQDiscontinuedIND
FDA suspends IND for IXCHIQ due to new SAE reported abroad
chikungunyasource ↗
◆Oral PresentationPresentation
Valneva management to meet investors at J.P. Morgan Healthcare Conference
◆Topline ReadoutVLA15FiledClinical Data
Topline results from VALOR trial expected in first half of 2026
Lyme diseasesource ↗
◆Topline ReadoutClinical Data
Pivotal data readout for Lyme disease vaccine expected in H1 2026
Lyme diseasesource ↗
◆Topline ReadoutClinical Data
Phase 3 pivotal results for Lyme disease vaccine expected H1 2026
Lyme diseasesource ↗
▼BLA SubmissionIXCHIQDiscontinuedRegulatory Filing
Voluntary withdrawal of BLA and IND for IXCHIQ in the US
Chikungunyasource ↗
▼IND WithdrawalIXCHIQDiscontinuedIND
Voluntary withdrawal of BLA and IND for IXCHIQ in the US
Chikungunyasource ↗
▲Product LaunchIXIAROPost-Market
CSL Seqirus to start commercializing IXIARO in Germany
Japanese Encephalitissource ↗
▲Product LaunchDUKORALPost-Market
CSL Seqirus to start commercializing DUKORAL in Germany
cholera/ETECsource ↗
▲Partnership / LicenseIXIAROCorporate
CSL Seqirus to commercialize IXIARO in Germany from January 2026
Japanese encephalitissource ↗
▲Partnership / LicenseDUKORALCorporate
CSL Seqirus to commercialize DUKORAL in Germany from January 2026
cholera/ETEC-diarrheasource ↗
▲Product LaunchIXCHIQDiscontinuedPost-Market
Pilot Vaccination Campaign in Brazil ongoing with ~50,000 vaccinated
Chikungunyasource ↗
Past FDA Catalysts and PDUFA Decisions
How VALN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | VLA15 (VALOR) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$42M
Pipeline Value
$383M
Commercial Value
Overvalued
Valuation Signal
6
Drugs Scored
0.3x
rNPV / MCap
Top 61%
Micro Cap(rank 402 of 658)
Percentile Rank
Valneva SE faces pipeline headwinds (33/100), with $163M risk-adjusted pipeline value, led by VLA1553 full dose in Chikungunya Virus Infection (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), converted from EUR to USD, to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K)) Revenue $166.7M x 2.3 = $383M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| IXIARO | $102M | $125M | -18% |
| DUKORAL | $34M | $41M | -16% |
| Third-party | $10M | $40M | -74.5% |
| IXCHIQ | $6M | $12M | -48.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VLA1553 full dose Monoclonal antibodyCompletedNCT06106581 | Chikungunya Virus Infection | Phase 2 | COMPLETED | 304 | Jul 2, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every VALN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VALN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.3 % (-25 %) | 11.98 M | 2.29 M |
VALN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VALN ranks across every disease it competes in
Competitive Position is a premium feature
See how VALN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVALN News
VALN▲ +0.9%today
Valneva fait un point sur l’utilisation d’IXCHIQ® au Royaume-Uni
Valneva SE announced the revocation of IXCHIQ®'s market authorization in the UK following a safety evaluation by the Commission on Human Medicines. This decision is based on known safety data and does not affect its availability in other regions. Valneva maintains that the benefit-risk profile of IXCHIQ® is favorable and will not appeal the decision due to limited financial impact.
Read more →VALN▲ +0.9%today
Valneva Provides Update on IXCHIQ® in the United Kingdom
Valneva SE announced the revocation of the UK marketing authorization for IXCHIQ® by the Medicines and Healthcare products Regulatory Agency (MHRA) following a benefit-risk assessment. The decision was based on previous safety data and does not affect IXCHIQ®'s licenses in other regions. Valneva will not appeal the decision, citing minimal financial impact and a strategic focus on endemic territories.
Read more →VALNDeclaration of shares and voting rights - Status as of August 31, 2026
Valneva has issued a declaration regarding its shares and voting rights status as of August 31, 2026. This declaration, dated September 4, 2026, includes details on the theoretical and net voting rights associated with its shares. The information pertains to the regulatory requirements set by the AMF General Regulations.
Read more →VALNValneva Half-Year 2026 Financial Report
Valneva SE released its Half-Year 2026 Financial Report, highlighting strong financial performance. The report also noted that the marketing authorization application for its Lyme disease vaccine candidate, developed in collaboration with Pfizer, was validated by the European Medicines Agency. This application is based on positive results from the Phase 3 VALOR trial.
Read more →VALNRapport Semestriel 2026 Valneva
Valneva SE has reported positive developments regarding its Lyme disease vaccine candidate, which is a collaboration with Pfizer. The European Medicines Agency has validated their marketing authorization application based on promising results from the Phase 3 VALOR trial. This marks a significant step forward for Valneva in the vaccine market.
Read more →VALNValneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Valneva SE reported its financial results for the first half of 2026, reaffirming its product sales guidance of €135-150 million. The company holds a strong cash position of €121.5 million, aided by a recent capital raise. However, it faced a net loss of €63.3 million, significantly higher than the previous year's loss, primarily due to lower sales and one-time costs. Regulatory decisions for its Lyme disease vaccine candidate are anticipated within the next year.
Read more →VALNValneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Valneva SE announced it will report its first half 2026 financial results on August 13, 2026. A live webcast will be held to discuss these results and provide a business update. The company specializes in developing vaccines for infectious diseases and has a strong portfolio of vaccine candidates.
Read more →VALNValneva Announces Successful Outcome of its Annual General Meeting
Valneva SE successfully held its Annual General Meeting in Lyon, where shareholders approved all proposed resolutions. Key decisions included the approval of financial statements and the reappointment of several board members. Dr. Gerd Zettlmeissl was appointed as the new Chair of the Board, succeeding Anne-Marie Graffin, who will continue as Vice-chair.
Read more →VALNValneva Announces Availability of Documentation for its Annual General Meeting
Valneva SE has announced the availability of documentation for its Annual General Meeting scheduled for June 25, 2026. Shareholders can access the preliminary notice, agenda, and draft resolutions online or request them via email. The company emphasizes its commitment to transparency and shareholder engagement.
Read more →VALNVALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026
Valneva has issued a declaration regarding its shares and voting rights as of May 31, 2026. The declaration was made on June 3, 2026, and includes details about theoretical and net voting rights. This information is relevant for shareholders and stakeholders in understanding the company's governance structure.
Read more →VALNValneva to Participate at U.S. and European Investor Conferences in June
Valneva SE announced its participation in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Oddo BHF Nextcap Forum. Key discussions will focus on Valneva's commercial stage vaccines, particularly the Lyme Disease vaccine candidate LB6V, which has shown promising Phase 3 results. The company will also engage with medical professionals at the Northern European Conference on Travel Medicine.
Read more →VALNValneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Valneva SE reported its financial results for Q1 2026, showing total revenues of €30.9 million, a significant decline from €49.2 million in the same quarter of 2025. The company also experienced an increased net loss of €32.1 million due to various operational challenges. In response, Valneva is implementing cost-saving measures and adjusting its sales guidance for the year. The company remains focused on its proprietary vaccine products and strategic initiatives.
Read more →VALNValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Valneva SE announced it will report its first quarter 2026 financial results on May 13, 2026. A live webcast will be hosted to discuss these results and provide a business update. The company focuses on developing vaccines for infectious diseases and has a strong pipeline, including a Lyme disease vaccine candidate partnered with Pfizer.
Read more →VALNVALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Valneva has issued a declaration regarding its shares and voting rights as of April 30, 2026, with interim information updated as of May 5, 2026. The declaration includes details about the theoretical and net voting rights associated with the company's shares. This information is crucial for understanding shareholder voting power and compliance with regulatory requirements.
Read more →VALNValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Valneva SE has announced it will report its first quarter 2026 financial results on May 13, 2026. The company will host a live webcast to discuss these results and provide a business update. Valneva specializes in developing vaccines for infectious diseases and has a strong pipeline, including a Lyme disease vaccine candidate.
Read more →VALNValneva Announces the Successful Completion of an €84 million Reserved Offering
Valneva SE has successfully completed a reserved offering, raising €84 million to support its vaccine pipeline and general corporate purposes. The offering attracted both existing and new investors, with a closing date set for May 5, 2026. The funds will be allocated equally between advancing vaccine candidates and working capital needs.
Read more →VALNValneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Valneva SE will participate in the 26th World Vaccine Congress in Washington, D.C., from March 31 to April 2, 2026. CEO Thomas Lingelbach and senior executives will present updates on their chikungunya vaccine, IXCHIQ®, which is undergoing a pilot vaccination campaign in Brazil. The event will also feature discussions on vaccine development and partnership opportunities.
Read more →VALNValneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Valneva SE will participate in the 26th World Vaccine Congress from March 31 to April 2, 2026, in Washington, D.C. The company's CEO and senior executives will present updates on their chikungunya vaccine and engage in discussions on vaccine development. Valneva is also launching a pilot vaccination campaign in Brazil for its chikungunya vaccine, IXCHIQ®, with over 12,000 people vaccinated.
Read more →VALNValneva Reports Full Year 2025 Audited Consolidated Financial Results
Valneva SE reported its audited financial results for 2025, showing total revenues of €174.7 million, slightly up from the previous year. The company highlighted a strong cash position of €109.7 million and a significant reduction in operating cash burn. Looking ahead, Valneva anticipates a transformative year in 2026 with Phase 3 data for its Lyme disease vaccine expected in the first half of the year.
Read more →VALNValneva gibt die konsolidierten geprüften Finanzergebnisse für das Gesamtjahr 2025 bekannt
Valneva SE reported consolidated financial results for the year ending December 31, 2025, showing a total revenue of €174.7 million, consistent with forecasts. The company highlighted a strong liquidity position of €109.7 million and a reduced operational cash burn. Looking ahead, 2026 is anticipated to be pivotal with Phase 3 data for its Lyme disease vaccine expected in the first half of the year.
Read more →About Valneva SE
BIOPHARMAWATCH ELITE PLUS
Trade the next VALN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime